Compare Intuit Inc. (INTU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Intuit Inc. trades at $332.64 (market cap $92.03B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Intuit Inc. pays a 1.43% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Intuit Inc. nearer its low. Which is the better fit depends on your goals.
| INTU | XBI | |
|---|---|---|
Market Cap | $92.03B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $717.21 | $164.28 |
52-Week Low | $255.07 | $86.92 |
Enterprise Value | $90.49B | — |
Dividend Yield | 1.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.
The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
